Effect of the concurrent LHRH antagonist administration with a LHRH superagonist in rats

The purpose of this study was to investigate the effect of a novel LHRH antagonist, Orntide acetate, on the initial testosterone elevation in rats during treatment with a LHRH superagonist, Leuprolide acetate.

Thirteen groups of a rat animal model were administered either liquid Orntide or Orntide PLGA microspheres before or simultaneously with Leuprolide injections. Serum levels of testosterone were monitored during the time course of the study using a radioimmunoassay method.

Administration of a single daily dose of liquid Orntide resulted in testosterone suppression within 6 h to levels below 0.5 ng/ml (castration level). However, combined administration of liquid Orntide and liquid Leuprolide did not have a significant effect on the initial testosterone elevation in studied rats. Similarly, there was no effect when liquid Orntide was co-administered with Leuprolide microspheres. Administration of Orntide microspheres 48 h before Leuprolide microspheres suppressed testosterone levels below the castration level within 24 h, however, did not prevent a rise in testosterone serum concentration upon administration of Leuprolide microspheres. Also, a second testosterone peak was observed between days 3 and 15 in the animals which were simultaneously treated with Orntide microspheres and Leuprolide microspheres.

Orntide acetate was found to be an effective LHRH antagonist with a rapid onset of pharmacological action and a short biological half-life. Administration of a single dose of liquid Orntide or Orntide microspheres, resulted in rapid testosterone suppression without an initial elevation, as seen with LHRH superagonists. However, combined administration of Orntide and Leuprolide did not have an effect on the initial testosterone elevation in rats.